Intra-atrial delivery of human cardiac extracellular vesicles completely prevented spontaneous postoperative atrial fibrillation and reduced inducible AF in porcine sterile pericarditis models.
Does targeted intra-atrial delivery of human cardiac extracellular vesicles prevent postoperative atrial fibrillation in rat and porcine sterile pericarditis models?
Intra-atrial delivery of human cardiac extracellular vesicles effectively prevents postoperative atrial fibrillation and reduces atrial inflammation and fibrosis in preclinical models, supporting its potential as a biologic therapy.
Targeted intra-atrial delivery of GMP-grade human cardiac extracellular vesicles (EVs) was evaluated for prevention of postoperative atrial fibrillation (AF). EVs were manufactured under serum-free, xenogen-free GMP-compatible conditions and tested in rat and porcine sterile pericarditis models. In rats, intra-atrial EV delivery resulted in selective atrial retention without systemic toxicity. In pigs, EV administration was technically feasible, well tolerated, and completely prevented spontaneous AF while significantly reducing inducible AF. EV therapy also attenuated atrial inflammation and fibrosis without adverse end-organ effects. These findings support localized cardiac EV therapy as a first-in-human-ready, disease-modifying biologic strategy for postoperative AF prevention.
Ahmed et al. (Wed,) conducted a other in Postoperative atrial fibrillation. GMP-grade human cardiac extracellular vesicles (EVs) was evaluated on Spontaneous and inducible postoperative atrial fibrillation. Intra-atrial delivery of human cardiac extracellular vesicles completely prevented spontaneous postoperative atrial fibrillation and reduced inducible AF in porcine sterile pericarditis models.